The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Treating patients with myelofibrosis who are intolerant to or develop resistance to JAK inhibitors
Peter te Boekhorst, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, discusses the treatment of patients with myelofibrosis (MF) who are intolerant to or develop resistance to JAK inhibitors, outlining the current therapeutic approaches utilized in this setting and mentioning some combination therapies that are under investigation. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
